Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2025 Apr 1;179(4):465-467.
doi: 10.1001/jamapediatrics.2024.6774.

Prognostication and Biomarker Potential of C26:0 Lysophosphatidylcholine in Adrenoleukodystrophy

Charles J Billington Jr  1 , Arpana Rayannavar  2 , Rebecca Tryon  3 , Tory Kaye  4 , Ashish Gupta  3 , Troy C Lund  3 , Aida Lteif  5 , Katherine L Adriatico  6 , Paul J Orchard  3 , Bradley S Miller  2 , Nishitha R Pillai  1
Affiliations
Comment

Prognostication and Biomarker Potential of C26:0 Lysophosphatidylcholine in Adrenoleukodystrophy

Charles J Billington Jr et al. JAMA Pediatr. .
No abstract available

Plain language summary

This cohort study conducted among Minnesota children diagnosed with adrenoleukodystrophy through newborn screening examines correlation of C26:0 lysophosphatidylcholine (C26LPC) with clinical phenotype over 5 years and recommends adjusting early childhood surveillance regimens in children with lower C26LPC levels.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Miller reported personal fees from AbbVie, Amgen, Ascendis, BioMarin, Bristol Myers Squibb, ENDO Pharmaceuticals, Eton Pharmaceuticals, GenSci, Sanofi, Soleno, and Tolmar outside the submitted work; funds paid to the University of Minnesota from Novo Nordisk and Pfizer; and grants from AbbVie, Aeterna Zentaris, Alexion, Foresee, Lumo Pharma, Novo Nordisk, Opko Health, Pfizer, and Sangamo outside the submitted work. No other disclosures were reported.

Comment on

References

    1. Engelen M, van Ballegoij WJC, Mallack EJ, et al. . International recommendations for the diagnosis and management of patients with adrenoleukodystrophy: a consensus-based approach. Neurology. 2022;99(21):940-951. doi:10.1212/WNL.0000000000201374 - DOI - PMC - PubMed
    1. Jaspers YRJ, Yska HAF, Bergner CG, et al. . Lipidomic biomarkers in plasma correlate with disease severity in adrenoleukodystrophy. Commun Med (Lond). 2024;4(1):175. doi:10.1038/s43856-024-00605-9 - DOI - PMC - PubMed
    1. Palakuzhiyil SV, Christopher R, Chandra SR. Deciphering the modifiers for phenotypic variability of X-linked adrenoleukodystrophy. World J Biol Chem. 2020;11(3):99-111. doi:10.4331/wjbc.v11.i3.99 - DOI - PMC - PubMed
    1. Mallack EJ, Turk BR, Yan H, et al. . MRI surveillance of boys with X-linked adrenoleukodystrophy identified by newborn screening: meta-analysis and consensus guidelines. J Inherited Metab Dis. 2021;44(3):728-739. doi:10.1002/jimd.12356 - DOI - PMC - PubMed
    1. Regelmann MO, Kamboj MK, Miller BS, et al. ; Pediatric Endocrine Society Drug and Therapeutics/Rare Diseases Committee . Adrenoleukodystrophy: guidance for adrenal surveillance in males identified by newborn screen. J Clin Endocrinol Metab. 2018;103(11):4324-4331. doi:10.1210/jc.2018-00920 - DOI - PubMed

LinkOut - more resources